Novo Nordisk A/S
As of Oct 23, 2026 close
- Market cap
- $173.22B
- P/E (TTM)
- 9.93
- Forward P/E
- 9.57
- Dividend yield
- 4.56%
- 52-week range
- $35.12$64.16
- Volume (live)
- -
- Avg. volume (3M)
- 12.75M
Novo Nordisk A/S (NVO) Stock Price & Financial Analysis
Novo Nordisk A/S Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $38.75 - $39.29 |
|---|---|
| 52-Week High | $64.16 |
| 52-Week Low | $35.12 |
| Open | $39.21 |
| Volume (last close) | 9.19M |
| Average Volume (3M) | 12.75M |
| Revenue (TTM) | 49.33B |
|---|---|
| Net Income (TTM) | 17.44B |
| Free Cash Flow (TTM) | 7.59B |
| EPS (TTM) | $3.92 |
| Profit Margin | 35.35% |
| Operating Margin | 43.13% |
| Return on Equity (ROE) | 52.62% |
| Debt to Equity | 0.63 |
| Annual Dividend | $1.80 |
|---|---|
| Dividend Yield | 4.56% |
| Payout Ratio | 45.72% |
| Last Dividend Ex-Date | Aug 17, 2026 |
| Market Cap | 173.22B |
|---|---|
| Shares Outstanding | 4.44B |
| P/E Ratio (TTM) | 9.93 |
| Forward P/E | 9.57 |
| Price to Sales (P/S) | 3.51 |
| Price to Book (P/B) | 5.23 |
| EV/EBITDA | 7.04 |
| 50-Day MA | $42.36 |
|---|---|
| 200-Day MA | $44.94 |
| 1-Year Change | −25.93% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Novo Nordisk A/S at a Glance
As of the Oct 23, 2026 close, Novo Nordisk A/S (NVO) has a market capitalization of $173.22B. The stock trades at 9.9× trailing earnings, 9.6× forward earnings and 3.5× sales. Over the trailing twelve months it earned $17.44B on revenue of $49.33B (a 35.4% profit margin) and generated $7.59B of free cash flow. Revenue grew 5.6% year over year.
As of its latest reported balance sheet, it holds $6.66B in cash and securities against $20.98B of debt, a net debt position of $14.32B.
Novo Nordisk A/S pays a semi-annual dividend totaling $1.80 per share a year, a 4.56% yield at the Oct 23, 2026 close, with a 46% payout ratio and 6 consecutive years of dividend increases.
The share price is down 25.9% over the past year. At $39.05 (the Oct 23, 2026 close) it sits near the bottom of its 52-week range of $35.12 to $64.16, below its 200-day moving average of $44.94.
Based on 14 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $42.53, 8.9% above the Oct 23, 2026 close.
Frequently Asked Questions About Novo Nordisk A/S
What is the current stock price for NVO?
As of the Oct 23, 2026 close, NVO stock trades at $39.05. The 52-week range is $35.12–$64.16, with a day range of $38.75–$39.29.
What is the P/E ratio for NVO?
As of the Oct 23, 2026 close, Novo Nordisk A/S's trailing twelve-month (TTM) P/E ratio is 9.9, meaning investors pay $9.9 for every $1 of annual earnings. The forward P/E is 9.6, reflecting analyst expectations for future earnings. Novo Nordisk A/S operates in the Healthcare sector.
Does NVO pay dividends?
Yes, Novo Nordisk A/S pays a 4.56% annual dividend yield as of the Oct 23, 2026 close ($1.80 per share a year). The trailing twelve-month payout ratio is 45.7%. The most recent ex-dividend date was August 17, 2026.
What do analysts recommend for NVO?
Based on ratings from 14 professional analysts over the last 90 days, the consensus for NVO is Hold. The average 12-month price target is $42.53, a 8.9% upside from the Oct 23, 2026 close of $39.05.
What is the market cap of NVO?
As of the Oct 23, 2026 close, Novo Nordisk A/S's market capitalization is $173.22B, classifying it as a large-cap company. Novo Nordisk A/S operates in the Healthcare sector within the Drug Manufacturers - General industry.